A phase I trial (NCT04595747) is currently testing the combination of pemigatinib plus olaparib in solid tumours harbouring FGFR2 alterations, including a GIST expansion cohort [60]. This evidence concerns the gene FGFR2 and gastrointestinal stromal tumor.